Halometasone monohydrate 0.05% in occupational contact dermatitis: A clinicoepidemiological study - HALOCD

SELF0 个研究点目标入组 150 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•All patients with pruritic eczematous conditions that started or aggravated for the first time after joining the present occupation will be included. The diagnosis of occupational contact dermatitis will be done based on taking detailed medical and occupational history and the presence of clinical signs and symptoms including pruritus and eczema.
•Lesions over all areas, including exposed as well as covered areas, will be included unless they are solely restricted to covered areas/ groins or genitalia.

•The diseases excluded were infective diseases like scabies, fungal infections, bacterial infections and all noneczematous dermatoses like psoriasis and lichen planus, even if associated with itching.
•Lesions solely affecting the groins, genitals or covered areas.
•Patients who are already under treatment for the presenting conditions.
•Patients with history of hypersensitivity to topical steroids.
•Patients (including severe/extensive eczema) in need of any form of treatment that influences the healing of the lesion such as topical treatment other than trial preparation, topical radiation therapy, systemic medication with antibiotics, antimicrobials, antihistaminics, cytostatics, corticosteroids, or ACTH will also be excluded.
•Pregnant and nursing women, patients with history of cardiovascular, hematological, pancreatic, metabolic, neurological, or clinically significant laboratory abnormalities which would interfere with patient participation in the study or evaluation of patientâ??s response to therapy were excluded from screening.

发起方

SELF